Mercury Biopharmaceutical Corporation
6932
Rank in Stocks
#21205
Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury... Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly boost the bioavailability of active pharmaceutical ingredients, leading to a reduction in required drug dosages and fewer adverse effects. Their development pipeline currently addresses a variety of ailments, such as erectile dysfunction, pulmonary hypertension, sleep disturbances, benign prostatic hyperplasia, angina, migraines, hypertension, and pain management.
Share Price
$0.16796937
Last synced: 2026-11-10
Market Cap
$71.83M
Change (1 day)
5.35%
Change (1 year)
-43.23%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Mercury Biopharmaceutical Corporation (6932)
Category
Healthcare
EPS for Mercury Biopharmaceutical Corporation (6932)
EPS as of June 2026 TTM: $0.00
According to Mercury Biopharmaceutical Corporation's latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of $-0.01, a decrease compared to its 2024 EPS of 0.00.
EPS history for Mercury Biopharmaceutical Corporation from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -63.00% |
| 2025 | $-0.01 | 37.84% |
| 2024 | 0.00 | 2.78% |
| 2023 | 0.00 | 33.33% |
| 2022 | 0.00 | 285.71% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -175,813.51% |
DE
|
|
| $6.08 | -164,359.46% |
DE
|
|
| $1.55 | -42,008.11% |
JP
|
|
| $3.66 | -99,018.92% |
CH
|
|
| $0.45 | -12,262.16% |
IL
|
Questions about Mercury Biopharmaceutical Corporation's earnings per share (EPS)
What is Mercury Biopharmaceutical Corporation's earnings per share (EPS)?
Mercury Biopharmaceutical Corporation's earnings per share (EPS) over the last twelve months is $0.00, as of Jun 2026.
What was Mercury Biopharmaceutical Corporation's earnings per share (EPS) in 2025?
In 2025, Mercury Biopharmaceutical Corporation's earnings per share (EPS) was $-0.01, compared with 0.00 in 2024.
How has Mercury Biopharmaceutical Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Mercury Biopharmaceutical Corporation's earnings per share (EPS) was highest in 2024 (0.00) and lowest in 2025 ($-0.01).
How does Mercury Biopharmaceutical Corporation's earnings per share (EPS) compare with similar companies?
Mercury Biopharmaceutical Corporation's earnings per share (EPS) ($0.00) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.